Strategies are needed to overcome resistance to immune checkpoint inhibitors in patients with cancer. An erythrocyte–antibody conjugate for the delivery of anti-PD-1 is now shown to favorably reshape ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results